Humeral Shaft Fractures : Outcomes of Straight Percutaneous Intramedullary Nailing With Dynamic Distal Locking

NCT06999018 | Completed

• 1 other identifier: 0013_HUMERUS
• Study Type: observational
• Target: 76
• Locations: 1 country
• Sites: 1

Brief Summary

This study looks at how many healthcare workers at CHSD have developed antibodies against COVID-19 after the second and third waves of the pandemic and following vaccination. By testing blood samples, we want to understand how well healthcare workers are protected, which work areas might be more at risk, and how immunity changes over time after infection or vaccination.

Conditions

COVID-19; Coronavirus Infections; Seroprevalence; Vaccination; Health Care Workers

Outcome Measures

Primary Outcomes (1)

• The seroprevalence of SARS-CoV-2 antibodies among healthcare workers at CHSD following COVID-19 vaccination and previous infection.

  January 2008 - June 2018

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consists of adult patients who underwent surgical treatment for closed, isolated, and displaced fractures of the humeral shaft. These patients were treated with percutaneous anterograde intramedullary nailing using dynamic distal locking between January 2008 and June 2018. The population includes both men and women, with a mean age of approximately 53 years. Only patients with fractures classified as type A, B, or C according to the AO/OTA classification and who were available for follow-up evaluation were included. Patients with open fractures, non-isolated or non-displaced fractures, or those lost to follow-up were excluded.

You may qualify if:

• Patients operated between January 2008 and June 2018
• Closed, isolated, displaced fractures of the humeral shaft
• Treatment by percutaneous anterograde intramedullary nailing with dynamic distal locking
• Availability for follow-up and evaluation (e.g., Constant score assessment in June 2018)

You may not qualify if:

• Open fractures
• Fractures that are not isolated or not displaced
• Patients lost to follow-up at the June 2018 evaluation (18 excluded)
• Lack of Constant score evaluation (patients not reviewed)

Sponsors & Collaborators

• Centre Hospitalier de Saint-Denis: lead

Study Sites (1)

France

Saint-Denis, France, France

Location

MeSH Terms

Conditions

COVID-19; Coronavirus Infections

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 22, 2025
• First Posted: May 31, 2025
• Study Start: January 1, 2020
• Primary Completion: January 1, 2021
• Study Completion: January 1, 2021
• Last Updated: May 31, 2025

Record last verified: 2025-05

Locations

FR (1)